In order to identify new kinases that could act as potential therapeutic targets to overcome BRAF inhibitor resistance, we screened a kinase inhibitor library of 274 compounds in 3 different melanoma cell lines that carry a mutated BRAF gene and are wild-type for NRAS: A375 cells with homozygous BRAF V600E and IGR37 and 501Mel cells heterozygous for BRAF V600E. This evidence concerns the gene BRAF and melanoma.